Illustration: Shoshana Gordon/Axios
Pharma giant Biogen has agreed to buy Apellis Pharmaceuticals for $5.6 billion, the companies announced Tuesday.
Why it matters: The deal will bolster Biogen's immunology and rare disease portfolios and immediately add sales revenue.
